CG Oncology announces data from Phase 3 BOND-003 trial

CG Oncology (CGON) announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer, NMBIC, unresponsive to Bacillus Calmette Guerin, BCG, demonstrating 74.5% of patients achieved a complete response, CR, at any time, after receiving treatment with cretostimogene as a single agent. The median duration of response, DOR, has not been reached but exceeds 27 months as of the data cutoff of September 30, 2024. These data will be presented today as a Late-Breaking Abstract at the Society of Urologic Oncology, SUO 25th Annual Meeting.